Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050…

Overview of attention for article published in Gynecologic Oncology, April 2025

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (86th percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

blogs: 1 blog
twitter: 5 X users

facebook: 1 Facebook page
bluesky: 2 Bluesky users

Readers on

mendeley: 7 Mendeley

So far, Altmetric has seen 6 X posts from 5 X users, with an upper bound of 9,825 followers.

#PublicaSalutIB 💉🍶 Oncologia de @SonEspases ha participat en un estudi on s'analitza l'impacte d’atezolizumab en la supervivència del càncer d’ovari https://t.co/PDHyeyUZ1E https://t.co/LBrbzPMzJd https://t.co/bkKsx98bOO

#PublicaSalutIB 💉🍶 Oncología de @SonEspases ha participado en un estudio donde se analiza el impacto de atezolizumab en la supervivencia del cáncer de ovario https://t.co/1E1Cnd411r https://t.co/z7AUafriR1 https://t.co/sSqEB3mks7

#PublicaSalutIB 💉🍶 Oncologia de @SonEspases ha participat en un estudi on s'analitza l'impacte d’atezolizumab en la supervivència del càncer d’ovari https://t.co/LyFEoyXI8C https://t.co/z7AUafriR1 https://t.co/RzvaazHIdJ

Retrospective analysis from IMagyn050 - Addition on Atezo to 1L chemo in poor prognostic ovarian ca (based on KELIM score) —> PFS benefit. https://t.co/ndWbacfa7V https://t.co/bW8CAVusbK

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 2 additional X posts.